CAMBRIDGE, Mass., Jan. 02, 2024 (GLO ## Article Body $95 million in development milestones payable over two years, as part of GSK license agreement CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing... ## Recent Company News - 2026-07-27 13:00 EST — [Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer](https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-81a269de) — Source: Spero Therapeutics - 2026-07-14 11:02 EST — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics - 2026-05-13 16:05 EST — [Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update) — Source: Spero Therapeutics - 2026-05-05 16:05 EST — [Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026) — Source: Spero Therapeutics - 2026-03-26 16:05 EST — [Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-and-provides-a-business-update) — Source: Spero Therapeutics ## Related News - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) - 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c) - 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec) - 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)